vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and S&T BANCORP INC (STBA). Click either name above to swap in a different company.

S&T BANCORP INC is the larger business by last-quarter revenue ($102.1M vs $77.6M, roughly 1.3× Bioceres Crop Solutions Corp.). S&T BANCORP INC runs the higher net margin — 34.4% vs -9.6%, a 44.0% gap on every dollar of revenue. Over the past eight quarters, S&T BANCORP INC's revenue compounded faster (2.6% CAGR vs -8.4%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

U.S. Bancorp is an American multinational banking institution headquartered in Minneapolis, Minnesota and incorporated in Delaware. It is the 5th-largest bank in the United States as of 2025. As the largest bank in the Midwestern United States, it is considered systemically important by the Financial Stability Board. It is the parent company of its primary operating entity, U.S. Bank National Association, which does business as U.S. Bank. The company provides banking, investment, mortgage, tr...

BIOX vs STBA — Head-to-Head

Bigger by revenue
STBA
STBA
1.3× larger
STBA
$102.1M
$77.6M
BIOX
Higher net margin
STBA
STBA
44.0% more per $
STBA
34.4%
-9.6%
BIOX
Faster 2-yr revenue CAGR
STBA
STBA
Annualised
STBA
2.6%
-8.4%
BIOX

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
BIOX
BIOX
STBA
STBA
Revenue
$77.6M
$102.1M
Net Profit
$-7.4M
$35.1M
Gross Margin
46.8%
Operating Margin
9.3%
Net Margin
-9.6%
34.4%
Revenue YoY
-16.8%
Net Profit YoY
-20.2%
5.0%
EPS (diluted)
$-0.12
$0.94

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
STBA
STBA
Q1 26
$102.1M
Q4 25
$105.3M
Q3 25
$77.6M
$103.0M
Q2 25
$100.1M
Q1 25
$60.6M
$93.8M
Q4 24
$98.8M
$94.3M
Q3 24
$93.3M
$96.4M
Q2 24
$96.9M
Net Profit
BIOX
BIOX
STBA
STBA
Q1 26
$35.1M
Q4 25
$34.0M
Q3 25
$-7.4M
$35.0M
Q2 25
$31.9M
Q1 25
$-1.6M
$33.4M
Q4 24
$605.2K
$33.1M
Q3 24
$-6.2M
$32.6M
Q2 24
$34.4M
Gross Margin
BIOX
BIOX
STBA
STBA
Q1 26
Q4 25
Q3 25
46.8%
Q2 25
Q1 25
39.4%
Q4 24
42.0%
Q3 24
40.2%
Q2 24
Operating Margin
BIOX
BIOX
STBA
STBA
Q1 26
Q4 25
40.3%
Q3 25
9.3%
42.6%
Q2 25
40.0%
Q1 25
1.5%
44.5%
Q4 24
14.5%
43.8%
Q3 24
2.5%
43.0%
Q2 24
44.2%
Net Margin
BIOX
BIOX
STBA
STBA
Q1 26
34.4%
Q4 25
32.3%
Q3 25
-9.6%
33.9%
Q2 25
31.9%
Q1 25
-2.6%
35.6%
Q4 24
0.6%
35.1%
Q3 24
-6.6%
33.8%
Q2 24
35.5%
EPS (diluted)
BIOX
BIOX
STBA
STBA
Q1 26
$0.94
Q4 25
$0.88
Q3 25
$-0.12
$0.91
Q2 25
$0.83
Q1 25
$-0.02
$0.87
Q4 24
$0.00
$0.86
Q3 24
$-0.10
$0.85
Q2 24
$0.89

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
STBA
STBA
Cash + ST InvestmentsLiquidity on hand
$15.5M
Total DebtLower is stronger
$100.8M
Stockholders' EquityBook value
$288.3M
$1.4B
Total Assets
$734.9M
$9.9B
Debt / EquityLower = less leverage
0.07×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
STBA
STBA
Q1 26
Q4 25
$163.4M
Q3 25
$15.5M
$196.2M
Q2 25
$203.1M
Q1 25
$38.5M
$211.8M
Q4 24
$29.2M
$244.8M
Q3 24
$32.3M
$228.1M
Q2 24
$246.3M
Total Debt
BIOX
BIOX
STBA
STBA
Q1 26
$100.8M
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Stockholders' Equity
BIOX
BIOX
STBA
STBA
Q1 26
$1.4B
Q4 25
$1.5B
Q3 25
$288.3M
$1.5B
Q2 25
$1.4B
Q1 25
$345.0M
$1.4B
Q4 24
$346.3M
$1.4B
Q3 24
$346.0M
$1.4B
Q2 24
$1.3B
Total Assets
BIOX
BIOX
STBA
STBA
Q1 26
$9.9B
Q4 25
$9.9B
Q3 25
$734.9M
$9.8B
Q2 25
$9.8B
Q1 25
$798.2M
$9.7B
Q4 24
$835.2M
$9.7B
Q3 24
$827.3M
$9.6B
Q2 24
$9.6B
Debt / Equity
BIOX
BIOX
STBA
STBA
Q1 26
0.07×
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
STBA
STBA
Operating Cash FlowLast quarter
$14.4M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
STBA
STBA
Q1 26
Q4 25
$133.6M
Q3 25
$14.4M
$40.5M
Q2 25
$28.3M
Q1 25
$23.3M
$28.7M
Q4 24
$-5.4M
$173.4M
Q3 24
$5.2M
$27.6M
Q2 24
$44.7M
Free Cash Flow
BIOX
BIOX
STBA
STBA
Q1 26
Q4 25
$128.8M
Q3 25
$39.9M
Q2 25
$27.1M
Q1 25
$27.0M
Q4 24
$170.4M
Q3 24
$26.9M
Q2 24
$43.9M
FCF Margin
BIOX
BIOX
STBA
STBA
Q1 26
Q4 25
122.4%
Q3 25
38.7%
Q2 25
27.1%
Q1 25
28.8%
Q4 24
180.7%
Q3 24
28.0%
Q2 24
45.3%
Capex Intensity
BIOX
BIOX
STBA
STBA
Q1 26
Q4 25
4.5%
Q3 25
0.6%
Q2 25
1.2%
Q1 25
1.8%
Q4 24
3.1%
Q3 24
0.7%
Q2 24
0.9%
Cash Conversion
BIOX
BIOX
STBA
STBA
Q1 26
Q4 25
3.93×
Q3 25
1.16×
Q2 25
0.89×
Q1 25
0.86×
Q4 24
-8.85×
5.24×
Q3 24
0.85×
Q2 24
1.30×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BIOX
BIOX

Segment breakdown not available.

STBA
STBA

Net Interest Income$88.4M87%
Noninterest Income$13.6M13%

Related Comparisons